AU Patent

AU2016328693B2 — Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer

Assigned to Janssen Pharmaceutica NV · Expires 2021-03-11 · 5y expired

What this patent protects

The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases…

USPTO Abstract

The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016328693B2
Jurisdiction
AU
Classification
—
Expires
2021-03-11
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.